- Home
- DYN vs BEAM Comparison
DYN vs BEAM Comparison
Compare DYN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- BEAM
- Stock Information
- Founded
- DYN 1984
- BEAM 2017
- Country
- DYN United States
- BEAM United States
- Employees
- DYN N/A
- BEAM N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DYN Health Care
- BEAM Health Care
- Exchange
- DYN Nasdaq
- BEAM Nasdaq
- Market Cap
- DYN 1.9B
- BEAM 1.7B
- IPO Year
- DYN 2020
- BEAM 2020
- Fundamental
- Price
- DYN $13.15
- BEAM $22.45
- Analyst Decision
- DYN Strong Buy
- BEAM Strong Buy
- Analyst Count
- DYN 14
- BEAM 10
- Target Price
- DYN $34.93
- BEAM $49.78
- AVG Volume (30 Days)
- DYN 2.2M
- BEAM 2.9M
- Earning Date
- DYN 11-11-2025
- BEAM 11-04-2025
- Dividend Yield
- DYN N/A
- BEAM N/A
- EPS Growth
- DYN N/A
- BEAM N/A
- EPS
- DYN N/A
- BEAM N/A
- Revenue
- DYN N/A
- BEAM $60,272,000.00
- Revenue This Year
- DYN N/A
- BEAM N/A
- Revenue Next Year
- DYN N/A
- BEAM $18.20
- P/E Ratio
- DYN N/A
- BEAM N/A
- Revenue Growth
- DYN N/A
- BEAM N/A
- 52 Week Low
- DYN $6.36
- BEAM $13.53
- 52 Week High
- DYN $37.08
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- DYN 56.80
- BEAM 65.37
- Support Level
- DYN $12.65
- BEAM $19.57
- Resistance Level
- DYN $13.68
- BEAM $21.59
- Average True Range (ATR)
- DYN 0.67
- BEAM 1.47
- MACD
- DYN -0.16
- BEAM 0.53
- Stochastic Oscillator
- DYN 30.72
- BEAM 85.28
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.